Medicure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Medicure şirketinin toplam hissedar öz sermayesi CA$19.5M ve toplam borcu CA$0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$28.2M ve CA$8.7M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CA$0

Borç

Faiz karşılama oranı	n/a
Nakit	CA$5.85m
Eşitlik	CA$19.54m
Toplam yükümlülükler	CA$8.70m
Toplam varlıklar	CA$28.24m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: NGQ1 'nin kısa vadeli varlıkları ( CA$15.9M ) kısa vadeli yükümlülüklerini ( CA$8.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: NGQ1 şirketinin kısa vadeli varlıkları ( CA$15.9M ) uzun vadeli yükümlülüklerini ( CA$187.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: NGQ1 borçsuzdur.

Borcun Azaltılması: NGQ1 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: Kârsız olan NGQ1 mevcut pozitif serbest nakit akışı seviyesini koruduğu takdirde 3 yıldan fazla yetecek nakit pistine sahip olacaktır.

Tahmini Nakit Akışı: NGQ1 kârlı değildir ancak serbest nakit akışının pozitif olması ve yılda % 28.4 oranında büyümesi nedeniyle 3 yıldan fazla bir süre yetecek nakit akışına sahiptir.

Medicure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Medicure Inc. Announces Resignation of Kimberly Kramchynsky as Member of the Board of Directors

Medicure Inc. to Report Q3, 2024 Results on Nov 25, 2024

Second quarter 2024 earnings released: CA$0.12 loss per share (vs CA$0.024 profit in 2Q 2023)

Now 26% undervalued after recent price drop

Medicure Inc. Appoints Kimberly Kramchynsky, Known as Kim Kline as Director

First quarter 2024 earnings released

Now 26% undervalued after recent price drop

Now 25% undervalued after recent price drop

Medicure Inc., Annual General Meeting, May 28, 2024

Full year 2023 earnings released: CA$0.088 loss per share (vs CA$0.13 profit in FY 2022)

Medicure Inc. to Report Fiscal Year 2023 Results on Apr 08, 2024

Investor sentiment improves as stock rises 16%

Investor sentiment improves as stock rises 29%

Medicure Inc. Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease

Third quarter 2023 earnings released: EPS: CA$0.01 (vs CA$0.11 in 3Q 2022)

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 20%

Second quarter 2023 earnings released: EPS: CA$0.02 (vs CA$0.067 loss in 2Q 2022)

Medicure Inc. to Report Q2, 2023 Results on Jul 28, 2023

First quarter 2023 earnings released: EPS: CA$0.03 (vs CA$0.047 in 1Q 2022)

Full year 2022 earnings released: EPS: CA$0.13 (vs CA$0.071 loss in FY 2021)

Medicure Inc. Announces Resignation of Gerald McDole as Member of the Board of Directors

Third quarter 2022 earnings released: EPS: CA$0.11 (vs CA$0.092 loss in 3Q 2021)

Medicure Inc. to Report Q3, 2022 Results on Nov 25, 2022

Insufficient new directors

Second quarter 2022 earnings released: CA$0.067 loss per share (vs CA$0.062 loss in 2Q 2021)

Medicure Inc. to Report Q2, 2022 Results on Aug 24, 2022

Medicure Inc. Appoints James Kinley as Director

Investor sentiment improved over the past week

First quarter 2022 earnings released

Medicure Inc. Appoints Haaris Uddin as Chief Financial Officer, Effective June 1, 2022

Full year 2021 earnings released: CA$0.07 loss per share (vs CA$0.64 loss in FY 2020)

Insufficient new directors

Medicure Inc., Annual General Meeting, Jun 16, 2022

Medicure Plans to Launch Innovative E-Commerce Pharmacy Platform Offering Hundreds of Medications Directly to Millions of Americans

Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint

Second quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.002 profit in 2Q 2020)

CFO & Secretary has left the company

First quarter 2021 earnings released

Full year 2020 earnings released

New 90-day high: €1.10

Medicure Announces Early Completion of Enrollment for iSPASM

New 90-day high: €0.88

New 90-day high: €0.69

New 90-day low: €0.49

Medicure Inc. to Report Q3, 2020 Results on Nov 11, 2020

New 90-day low: €0.51

New 90-day low: €0.59

New 90-day high - €0.78

First half earnings released

Medicure Inc. to Report Q2, 2020 Results on Aug 11, 2020

Medicure Inc.(TSXV:MPH) dropped from S&P/TSX Venture Composite Index

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin